ArticleFrontiers in global women's health2024
Hormone replacement therapy perspectives.
Article in Frontiers in global women's health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07163442 (One-year Results of Bioidentical Hormone Replacement Therapy in Postmenopausal Women), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
One-year Results of Bioidentical Hormone Replacement Therapy in Postmenopausal Women
Who cites it
3 citing papers in PubMed.
- Sexual Dimorphism in Cardiometabolic Diseases: From Development to Senescence and Therapeutic Approaches.Cells · 2025Review
- Updates in Hormone Replacement Therapy for Survivors of Gynecologic Cancers.Current treatment options in oncology · 2025Review
- Hormone replacement therapy for menopausal mood swings and sleep quality: The current evidence.World journal of psychiatry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hormone replacement therapy (HRT), also known as menopausal hormone therapy (MHT), was looked upon as a fountain of youth that kept women young and reduced cardiovascular disease. This led to a large-scale study called the Women's Health Initiative (WHI) that was conducted to show the cardiovascular benefits of HRT. This study was suspended early because of adverse side effects. The USFDA responded by slapping a "black box" warning on all HRT products. USFDA-approved bioidentical HRT formulations are safe and effective. We propose that these formulations have the "black box" warning removed so that doctors feel more confident in prescribing these products for symptoms of menopause and chronic conditions such as cardiovascular health. We propose eliminating the sale of products containing medroxyprogesterone acetate (MPA) because of the increased risk of heart attacks and breast cancers associated with this medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.